Arcus Biosciences, Inc. (RCUS)
NYSE: RCUS · Real-Time Price · USD
11.07
+0.33 (3.07%)
At close: Feb 21, 2025, 4:00 PM
11.20
+0.13 (1.17%)
After-hours: Feb 21, 2025, 7:45 PM EST
Arcus Biosciences Revenue
Arcus Biosciences had revenue of $48.00M in the quarter ending September 30, 2024, with 50.00% growth. This brings the company's revenue in the last twelve months to $263.00M, up 119.17% year-over-year. In the year 2023, Arcus Biosciences had annual revenue of $117.00M with 4.46% growth.
Revenue (ttm)
$263.00M
Revenue Growth
+119.17%
P/S Ratio
3.62
Revenue / Employee
$455,806
Employees
577
Market Cap
1.01B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
RCUS News
- 4 days ago - Arcus Biosciences Retains Rights to Casdatifan, a Potential Best-in-Class HIF-2a Inhibitor, and Announces Pricing of $150 Million Common Stock Offering - Business Wire
- 4 days ago - Arcus Biosciences, Inc. Announces Underwritten Offering of Common Stock - Business Wire
- 7 days ago - New Data Demonstrated Best-in-Class Potential for Casdatifan, a HIF-2a Inhibitor, in Patients with Metastatic Kidney Cancer - Business Wire
- 11 days ago - Arcus Biosciences Announces New Employment Inducement Grants - Business Wire
- 12 days ago - Arcus Biosciences to Present New Data from Casdatifan, a HIF-2a Inhibitor, in an Oral Presentation at the 2025 ASCO GU Symposium - Business Wire
- 4 weeks ago - Arcus Biosciences Appoints Richard Markus, M.D., Ph.D. as Chief Medical Officer - Business Wire
- 5 weeks ago - Arcus Biosciences: Many Important Oncology Catalysts Coming Up In 2025 - Seeking Alpha
- 5 weeks ago - Arcus: Excellent Pipeline And Collaborations, Cash Runway - Seeking Alpha